Disclosures for "Characterization of "Early-Start" Participants that Continued Receiving Donanemab in the TRAILBLAZER-ALZ 2 Long-Term Extension Period"
-
Dr. Schreiber has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Schreiber has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lilly. Dr. Schreiber has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for eisai. Dr. Schreiber has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for lilly. Dr. Schreiber has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for pfizer.
-
Author has nothing to disclose
-
Dr. Doty has received personal compensation for serving as an employee of Eli Lilly and Company, USA. Dr. Doty has stock in Eli Lilly and Company, USA.
-
Ms. Yang has nothing to disclose.
-
Dr. Sato has received personal compensation for serving as an employee of Eli Lilly and Company. Dr. Sato has stock in Eli Lilly and Company.
-
Dr. Zimmer has received personal compensation for serving as an employee of Eli Lilly & Company. Dr. Zimmer has stock in Eli Lilly & Company.